WATCH TV LIVE

NEWSMAX TV HEALTH FINANCE WORLD

Tags: esperion | cholesterol | drug | trial

New Cholesterol Drug Shows Promise

Tuesday, 17 March 2015 08:24 AM EDT

Esperion Therapeutics said its experimental drug showed greater reductions in cholesterol levels when compared with a placebo in a mid-stage study.

Patients taking doses of 120 mg and 180 mg of the drug, ETC-1002, showed 17 and 24 percent greater reduction in bad cholesterol levels.

The study was evaluating safety and effectiveness of the drug in patients with high cholesterol levels.

Click Here to comment on this article

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

Yes, Send Me News Alerts via email

(Optional for Local News)

Privacy: We never share your email address.

Join the Newsmax Community

Read and Post Comments
Please review Community Guidelines before posting a comment.

Find Your Condition

Cancer	Heart Disease
Obesity	Arthritis
Alzheimer's/Dementia	Digestive Problems
Cold/Flu	Depression
Allergies	High Cholesterol
Chronic Pain	Thyroid Disorders
Menopause	Osteoporosis
Autism	Anxiety
High Blood Pressure	Diabetes

More Conditions

TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.